
The Inflation Reduction Act and Cost Considerations for BTK Inhibitors
Panelists discuss how the inclusion of ibrutinib on the Inflation Reduction Act (IRA) negotiated drug price list could make it a more economically attractive first-line option, potentially influencing the sequencing of Bruton tyrosine kinase (BTK) inhibitors in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) treatment while considering other financial factors like insurance coverage, copays, and total out-of-pocket costs that impact patient access and treatment decisions.
Video content above is prompted by the following:
- With ibrutinib on the negotiated drug price list under the IRA, how might cost considerations influence first-line BTK inhibitor selection and subsequently shape second-line and beyond treatment choices in R/R CLL?
- Beyond the IRA, what role do broader economic factors, such as insurance coverage and out-of-pocket costs, play in treatment selection for patients with R/R CLL requiring BTK inhibitors?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.